A MEK inhibitor that suppresses MEK1 and MEK2 with IC50 of 0.92 and 1.8 nM and no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2. It has been approved by FDA, in combination with Tafilnar, for the treatment of metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation.https://www.bocsci.com/trametinib-cas-871700-17-3-item-84-307744.html
BOC Sciences is the chemistry division of Creative Dynamics Inc. headquartered in New York, USA. We leverage our wide spectrum of business in the fields of development, manufacturing, marketing, and distribution to help you make best-informed decisions tailored to your evolving needs for premium chemicals. Our complete suite of CRO services spans the entire molecule development pipeline including contract research for target identification, building blocks, compound synthesis, biochemical and ce...
View more >>
Basic Information
Business Type: Manufacturer
Product/Service (We Buy): 101 - 500 People
Year Established: 2005
Number of Employees: 101 - 500 People
Trade & Market
Main Markets: North America,Southeast Asia,Mid East,South America,Africa,Eastern Asia,Eastern Europe,Oceania,Western Europe
QA/QC: 0
Number of R&D Staff: 0
Total Annual Sales Volume: US$5 Million - US$10 Million
United States
